Mobile website
Archive > Volume 24 Issue 9 > 2017,24(9):929-937. DOI:10.3872/j.issn.1007-385X.2017.09.001 Prev Next
Expert Forum
The development trend of therapeutic monoclonal antibodies for cancer therapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Many advances in the treatment of cancer have been driven by the development of targeted therapies that inhibit oncogenic signaling pathways and tumor-associated angiogenesis, as well as by the therapies that acti-vate immune system to unleash antitumor immunity. Many clinically approved therapies, including monoclonal anti-bodies，antibody-drug conjugates，bispecific antibodies and immune checkpoints, have become important strategies for cancer treatment. Recently, tumor immunotherapy is becoming more and more popular, and antibody medicines acquiring above mentioned immune-modulating effects, such as increasing tumor antigenicity or promoting intratu-moral T cell infiltration, had achieved great clinical benefits; monoclonal antibody medicine in combination with tu-mor immunotherapy, molecular targeted antibody medicine, chemotherapy or small molecular inhibitors and even surgery, will further enlarge the application value of antibody medicines in tumor therapies.
Keywords:
Project Supported:
Project supported by the National Major Sci-entific and Technological Special Project for“Significant New DrugsDevelopment” （No. 2014ZX09201041-001）
Clc Number:
